BTC$60,654.00-0.59%
ETH$1,559.10-1.26%
USDT$0.9996-0.01%
BNB$573.34+0.04%
USDC$0.9997+0.01%
XRP$1.09-1.35%
SOL$61.91-3.12%
TRX$0.3237+0.86%
FIGR_HELOC$1.03+0.46%
DOGE$0.0814-0.42%
HYPE$56.44-5.27%
USDS$0.9997-0.02%
LEO$9.44-1.44%
RAIN$0.0128-1.63%
XLM$0.2116+5.14%
CC$0.1627+9.72%
BTC$60,654.00-0.59%
ETH$1,559.10-1.26%
USDT$0.9996-0.01%
BNB$573.34+0.04%
USDC$0.9997+0.01%
XRP$1.09-1.35%
SOL$61.91-3.12%
TRX$0.3237+0.86%
FIGR_HELOC$1.03+0.46%
DOGE$0.0814-0.42%
HYPE$56.44-5.27%
USDS$0.9997-0.02%
LEO$9.44-1.44%
RAIN$0.0128-1.63%
XLM$0.2116+5.14%
CC$0.1627+9.72%
Ryanair shares gained 2.08% in premarket trading after CEO Michael O'Leary reported strong summer bookings and rising prices.
Optical Cable Corporation's stock surged over 47% in premarket trading following the announcement of a strategic collaboration.
CoreWeave is going all-in for the prospect of AI demand. Is this bullishness warranted?
Both companies represent the most realistic eVTOL exposure, but Archer has an extra edge.
OpenAI publicly denounced Robinhood's tokenized shares offering, stating the tokens are not real equity.
Intel stock declined over 4% as reports emerged that the company may abandon efforts to sell its 18A chip manufacturing process to external customers.
Adobe stock fell 4.59% after Redburn-Atlantic downgraded shares to Sell, warning that generative AI tools are eroding the company's competitive advantage.
Centene Corporation withdrew its 2025 guidance after discovering that Health Insurance Marketplace morbidity trends were significantly higher than expected.
Without investing in hard assets, central banking ensures constant erosion of wealth.
Thumzup Media shares jumped 20.4% in premarket trading after announcing a $6.5 million registered direct offering.
Tesla stock plunged over 4% in premarket trading as tensions between Elon Musk and President Trump reignited over government spending.
Are Ripple’s prospects tied to the XRP token? Not quite.
Moderna's experimental flu vaccine demonstrated superior efficacy compared to standard flu vaccines in late-stage trials.